1	Rapid comparative evaluation of SARS-CoV-2 rapid point-of-care antigen tests
2	
3	Anna Denzler ^{1, †} , Max L. Jacobs ^{1, †} , Victoria Witte ¹ , Paul Schnitzler ² , Claudia M.
4	Denkinger ^{3,*} , Michael Knop ^{1,4,5,*}
5	
6	Affiliations:
7	¹ Center for Molecular Biology of Heidelberg University (ZMBH), Heidelberg,
8	Germany.
9	² Department of Infectious Diseases, Virology, Heidelberg University Hospital,
10	Heidelberg, Germany.
11	³ Department of Infectious Diseases, Division of Tropical Medicine, Heidelberg
12	University Hospital, Heidelberg, Germany.
13	⁴ German Cancer Research Center (DKFZ), Heidelberg, Germany.
14	⁵ DKFZ-ZMBH Alliance, Heidelberg, Germany.
15	* Corresponding authors.
16	[†] These authors contributed equally to this work.
17	
18 19	Keywords: Comparison of Antigen-detecting rapid diagnostic test; COVID-19; SARS-CoV-2; Testing sensitivity, non-functional AgPOC tests.
20	
21	
22	Corresponding authors:
23	Michael Knop
24 25	Center for Molecular and Cellular Biology Heidelberg, Heidelberg University, Heidelberg, Germany
26	m.knop@zmbh.uni-heidelberg.de
27	+49 6221 54 4213
28	Claudia M. Denkinger
29 30	Division of Tropical Medicine, Center for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany
31	Claudia.Denkinger@uni-heidelberg.de
32	+49 6221 56 36637

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 Abstract

Background: Currently, more than 500 different AgPOCTs for SARS-CoV-2 diagnostics are on sale (July 2021), for many of which no data about sensitivity other than self-acclaimed values by the manufacturers are available. In many cases these do not reflect real-life diagnostic sensitivities. Therefore, manufacturer-independent quality checks of available AgPOCTs are needed, given the potential implications of false-negative results.

40 **Objective:** The objective of this study was to develop a scalable approach for direct 41 comparison of the analytical sensitivities of commercially available SARS-CoV-2 42 antigen point-of-care tests (AgPOCTs) in order to rapidly identify poor performing 43 products.

44 **Methods:** We present a methodology for quick assessment of the sensitivity of 45 SARS-CoV-2 lateral flow test stripes suitable for quality evaluation of many different 46 products. We established reference samples with high, medium and low SARS-CoV-47 2 viral loads along with a SARS-CoV-2 negative control sample. Test samples were 48 used to semi-quantitatively assess the analytical sensitivities of 32 different 49 commercial AgPOCTs in a head-to-head comparison.

Results: Among 32 SARS-CoV-2 AgPOCTs tested, we observe sensitivity 50 differences across a broad range of viral loads (~7.0*10⁸ to ~1.7*10⁵ SARS-CoV-2 51 genome copies per ml). 23 AgPOCTs detected the Ct25 test sample (~1.4*10⁶ 52 copies/ ml), while only five tests detected the Ct28 test sample ($\sim 1.7^{*}10^{5}$ copies/ 53 ml). In the low range of analytical sensitivity we found three saliva spit tests only 54 delivering positive results for the Ct21 sample (~2.2*10⁷ copies/ ml). Comparison 55 with published data support our AgPOCT ranking. Importantly, we identified an 56 57 AgPOCT offered in many local drugstores and supermarkets, which did not reliably recognize the sample with highest viral load (Ct16 test sample with ~7.0*10⁸ copies/ 58 59 ml) leading to serious doubts in its usefulness in SARS-CoV-2 diagnostics.

60 **Conclusion:** The rapid sensitivity assessment procedure presented here provides 61 useful estimations on the analytical sensitivities of 32 AgPOCTs and identified a 62 widely-spread AgPOCT with concerningly low sensitivity.

63

64

Funding: The study was supported by the Ministry of Science, Research and Arts of the State of Baden-Wuerttemberg, Germany as well as internal funds from the Heidelberg University Hospital. The corresponding authors had access to all data at all time.

69

70 Introduction

71 In the SARS-CoV-2 pandemic, lateral flow antigen tests were developed as a rapid 72 alternative to SARS-CoV-2 reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)-based diagnostics. Because of their ease of use, lateral flow 73 74 antigen tests are applicable for point-of-care (POC) and self testing and can therefore be incorporated in the daily life to support viral containment (WHO, Interim guidance, 75 2020). These tests, in the following referred to as antigen point-of-care tests 76 (AgPOCTs), are meanwhile widely used for SARS-CoV-2 diagnostic and screening 77 78 purposes. Currently, several hundred different SARS-CoV-2 AgPOCTs brands are commercially available to meet the demand (545 products for professional use are 79 80 listed by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für 81 Arzneimittel und Medizinprodukte (BfArM)); as of July 27, 2021). However, 82 sensitivity and specificity of the tests are not systematically assessed.

If a test is used by a professional operator, it falls under the 'low-risk' category of the 83 84 European Union directive on In Vitro Diagnostics (IVD), which currently governs 85 marketing authorization for IVDs in Europe. Under this directive, manufacturers can still self-certify COVID-19 tests and waive independent verification of the tests before 86 87 they are marketed. The validation of the tests, which are offered online and in pharmacies, is therefore not assured in the view of the Paul Ehrlich Institute (PEI), 88 89 Federal Institute for Vaccines and Biomedical Products, Germany 90 (https://www.pei.de/DE/newsroom/hp-meldungen/2020/200323-covid-19-nat-

tests.html;jsessionid=F786872EBB85959AE8DA2B8FCB3ABE00.intranet222?nn=16
9730). There is also evidence of counterfeiting here. A new legislation governing
independent validation by specialized and certified reference laboratories is planned,
but will only become effective in March 2022 at the earliest.

If a test is distributed for layperson use, it falls under a 'higher-risk' category and 95 96 requires independent validation. This validation of sensitivity is currently performed by the PEI together with reference laboratories and a list with AgPOCTs passing their 97 98 criteria is provided (PEI, 2021). AgPOCTs failing the comparative evaluation by PEI will be removed from the list provided by BfArM. This list, however, comprises only 99 100 products, which were also registered for listing by manufacturers or distributors 101 (https://www.bfarm.de/DE/Medizinprodukte/Aufgaben/Spezialthemen/Antigentests/_n 102 ode.html), rendering the absence of an AgPOCT from this list difficult to interpret.

103 Many in-depth AgPOCT characterization studies show that AgPOCT sensitivities can 104 vary substantially. One study reporting on the validation of 122 AgPOCs has recently 105 been published (Scheiblauer et al., 2021). The authors found that 26 AgPOCTs do 106 not fulfill the required minimum sensitivity, clearly illustrating that guite a number of 107 circulating AgPOCT are insufficiently sensitive. In addition to this, significant brand-108 to-brand and lot-to-lot variations were observed (Dinnes et al, 2021). These 109 circumstances urge the need for an easy-to-use method to quickly assess AgPOCTs at market entry and periodically thereafter for post-implementation quality control. 110

111 In this study, we seeked to establish a procedure to rapidly evaluate a large number 112 of products for their sensitivity, using a small test sample panel and several tests per 113 product. For this we developed a strategy involving pooled samples and four different 114 dilution steps from high to low viral loads, and generated several hundred aliquots 115 thereof. Using this approach we then investigated 32 AgPOCTs, mainly tests 116 currently in use in the local area (Heidelberg, Germany). We compared the results 117 with data from the literature, which enabled us to draw conclusions on the validity of 118 our approach and the performance of the products investigated.

119 Methods

120 Study design

121 We tested the analytical sensitivity of a large number of commercially available 122 AqPOCTs by applying pooled samples from nasopharyngeal swabs with defined SARS-CoV-2 viral loads including Ct16, Ct21, Ct25 and Ct28 (~7.0*10⁸ to ~1.7*10⁵ 123 124 genome copies per ml) as well as a pooled sample obtained from SARS-CoV-2 125 negative tested persons. Pools were generated using anonymized remnant swab 126 sample material that had been collected for clinical diagnosis of SARS-CoV-2 127 infection by RT-qPCR carried out by the Center for Infectious Diseases, Virology, 128 Heidelberg University Hospital, Germany, Pharyngeal swab specimens were 129 collected through the nose (nasopharyngeal) and contained in viral transport medium 130 (VTM). Per test, 50 µl of the samples were mixed with the provided lysis buffer of 131 each AgPOCT and the tests were performed strictly according to the manufacturer's 132 instructions. After the recommended incubation time, images of the test chambers 133 were acquired using a Panasonic Lumix DMC-G70 camera equipped with a 134 Panasonic H-FS12060 objective. AgPOCTs were tested at least in duplicates with 135 the corresponding test samples. Test results were quantified by measuring the background-corrected signal intensities of the test (T) band versus control (C) band 136 137 in ImageJ (v1.53c) using the "Gels" analysis function usually used for guantification 138 of Western Blot bands. For qualitative evaluation of the visibility of the test bands 139 (positive versus negative score), RGB pictures of AqPOCT results from randomly 140 chosen replicates were evaluated independently by three individuals in a blinded 141 manner. Furthermore, all additional replicates of all AgPOCTs and test samples were 142 scored independently by another person.

143 **Preparation of test samples from nasopharyngeal swabs**

144 Anonymized, remnant nasopharyngeal swab samples positively and negatively 145 tested for SARS-CoV-2 were obtained between May and July 2021 from the the Center for Infectious Diseases, Virology, Heidelberg University Hospital, Germany. 146 147 Samples were stored in VTM. The Ct16, Ct21 and negative test samples were prepared by pooling of 12-15 nasopharyngeal swab samples. Cell debris and other 148 solids were removed by centrifugation at 400g for 10min and subsequent transfer of 149 150 the supernatant into a new tube. Viral RNA was isolated from pools by manual lysis 151 and automated RNA extraction using the QIAamp Viral RNA Mini kit (Qiagen) on a QIAcube Connect device (Qiagen). The cycle threshold (Ct) values of sample pools 152 153 were determined by RT-qPCR analysis using the LightMix[®] Modular Sarbecovirus

154 SARS-CoV-2 (TIB Molbiol) with the LightCycler® Multiplex RNA Virus Master

(Roche) and LightCycler480 II (Roche). Subsequently, pools were supplemented with 2 % TritonX-100 and cOmplete Ultra protease inhibitor (Roche) and if needed adjusted with dilution buffer [2 mg/ ml BSA, 0.9 % NaCl, protease inhibitor]. Ct25 and Ct28 test samples were prepared by dilution of the Ct21 test sample in the dilution buffer. Samples were aliquoted (120 μ l), immediately frozen on dry ice and stored at -80°C. For AgPOCT testing, samples were freshly thawed on ice before use. Test samples were validated using the SARS-CoV-2 Antigen Test by LumiraDx.

162 AgPOCTs evaluated in this study

We included a total of 32 AgPOCTs available at local supermarkets, pharmacies and 163 164 drugstores as well as on several online trade platforms (Table 1). Specific AgPOCTs will be referred to as the respective manufacturer's name (in bold in Table 1). The 165 166 inspected AqPOCTs include both, tests for professional in vitro diagnostics use (#1-14) as well as tests temporarily licensed for self-testing in Germany (#15-32) by the 167 168 Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und 169 Medizinprodukte (BfArM); Supplemental Figure S5). The majority of AgPOCTs 170 available were nasal or nasopharyngeal swab tests with the exception of BTNX, Ritter, Joinstar, Realy (#11-14) among the tests for professional use and Sanicom, 171 172 Hygisun, fameditec (#30-32) among the self tests, which are all saliva spit tests, as 173 well as Watmind (#29), which is a saliva swab test.

For Lepu medical (#20 in Table 1), the AgPOCT with poorest results in our study, we purchased different versions and additional batches for a more in-depth characterization (Table 2). **Table 1: AgPOCTs investigated in this study.** For each AgPOCT supplier, name, reference and LOT number are indicated. If tests obtained a temporary license for self-testing in Germany the corresponding BfArM GZ number is given as well. In addition, sample type and professional (pro) versus layman (lay) use is indicated. In the last column the type of distributor where AgPOCTs were purchased is noted.

#	Supplier	AgPOCT name	Specifications	Sample type	Use	Distributor
1	Abbott Rapid Diagnostics Jena GmbH	Panbio COVID-19 Ag Rapid test device (nasal)	REF: 41FK11 LOT: 41ADG244A	Nasal swab	pro	Online trade
2	Healgen Scientific Limited Liability Company	Coronavirus Ag Rapid Test Cassette (Swab)	REF: GCCOV-502a LOT: 2012650	Nasopharyngeal swab	pro	Online trade
3	RapiGEN, INC.	Biocredit COVID-19 Ag – One step Rapid Test	REF: G61RHA20 LOT: H073097SD	Nasopharyngeal swab	pro	Online trade
4	Beijing Beier Bioengeneering Co., Ltd	COVID-19 Antigen Rapid Test Kit	REF: not specified LOT: 20210201	Nasopharyngeal swab	pro	Online trade
5	möLab GmbH	mö-screen Testkit Corona Antigen	REF: 0230005B1 LOS: 2104072	Nasal/ nasopharyngeal swab	pro	Online trade
6	Biomerica, Inc.	COVID-19 Antigen Rapid Test	REF: 1509A-25I LOT: COV6686	Nasopharyngeal swab	pro	Online trade
7	Joysbio (Tianjin) Biotechnology Co., Ltd	JOYSBIO SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold)	REF: G10313 LOT: 2021011607	Nasopharyngeal swab	pro	Online trade
8	Safecare Biotech (Hangzhou) Co., Ltd	COVID-19 Antigen Rapid Test Kit (Swab)	REF: COV Ag-6012 LOT: COV21040606	Nasopharyngeal swab	pro	Online trade

9	Hangzhou Testsea	Testsealabs COVID-19 Antigen	REF: 2020013 vB/10	Nasal swab pro		Online trade
	Biotechnology Co., Ltd	Test Cassette	LOT: TL1C05			
10	ACON Biotech (Hangzhou) Co., Ltd	Flowflex SARS-Cov-2-Antigen- Schnelltest (Selbsttest)	REF: L031-11855 LOT: COV1030052	Nasal swab	pro	Online trade
11	BTNX Inc.	Rapid Response COVID-19	REF: COV-2C25B	Saliva (spit)	pro	Online trade
		Antigen Rapid Test Cassette	LOT: COVG21030089			
12	Joysbio (Tianjin)	bio (Tianjin) Easy Check Spit test SARS-CoV-		Saliva (spit)	pro	Online trade
	Biotechnology Co., Ltd/ Ritter	2 Antigen Rapid Test Kit (Colloidal Gold)	LOT: 20210202			
13 Joinstar Biomedical		COVID-19 Antigen Rapid Test	REF: RPBH12360	Saliva/ sputum	pro	Online trade
	Technology Co., Ltd.	(Latex)	LOT: COV2103002L	(spit), stool		
14	Hangzhou Realy Tech	Novel Coronavirus (SARS-CoV-	REF: K590516D	Saliva (spit)	pro	Online trade
	Co., Ltd	2) Antigen Rapid Test Device (Saliva)	LOT: 202101022			
15	nal von minden GmbH	NADAL COVID-19 Ag Test	REF: 243103N-20H	Nasal swab	lay	Online trade
			LOT: 175363			
			BfArM GZ: 5640-S-045/21			
16	SD Biosensor	SARS-CoV-2 Rapid Antigen Test	REF: 9901-NCOV-01G	Nasal swab	lay	Online trade
			LOT: QCO3900921			
			BfArM GZ: 5640-S-025/21			

17	Beijing Hotgen Biotech Co., Ltd	Coronavirus (2019-nCoV)- Antigentest	REF: 4260220532859 LOT: W2021032500/ W2021032602/ 1500	Nasal swab	lay	Supermarket Pharmacy
			BfArM GZ: 5640-S-057/21			
18	Guangzhou Wondfo	2019-nCoV Antigen Test (Lateral	REF: W634P0021	Nasal swab	lay	Supermarket
	Biotech Co., Ltd.	Flow Method)	LOT: W634104116			
			BfArM GZ: 5640-S-179/21			
19	Teda Laukoetter Technology GmbH	COVID-19 Antigen Schnelltest (kolloidales Gold) ANBIO Corona Antigen Nasentupfer	REF: A6061214 LOT: 2021046133/ 461310/036138	Nasal swab	lay	Drug store
			BfArM GZ: 5640-S-079/21			
20	Beijing Lepu medical Technology Co., Ltd	NASOCHECKcomofort SARS- CoV-2 Antigen-Schnelltest	REF: CG2701N LOT: 21CG2720X/ 18X	Nasal swab	lay	Drug store
			BfArM GZ: 5640-S-104/21			
21	Hangzhou Clongene Biotech Co., Ltd	COVID-19 Antigen Rapid Test	REF 6950921302636 LOT: 2021030161 BfArM GZ: 5640-S-168/21	Nasal swab	lay	Online trade
22	Hangzhou Laihe Biotech Co., Ltd	LYHER Novel Coronavirus (COVID-19) Antigen Test Kit	REF: 303036 LOT: 2103049/47/ 89-01	Nasal swab lay		Pharmacy
		(Colloidal Gold) NASAL	BfArM GZ: 5640-S-009/21			
23	MP Biomedicals Germany GmbH	Rapid SARS-Cov-2 Antigen Test Card	REF: 07AG6001BS LOT: 21033003	Nasal swab	Supermarket	
			BrArM GZ: 5640-S-076/21			

24	Xiamen Boson Biotech Co., Ltd	Rapid SARS-CoV-2 Antigen Test Card	REF: 1N40C5-4 LOT: 21040609	Nasal swab	lay	Supermarket			
	,		BfArM GZ: 5640-S-007/21						
25	NanoRepro AG	VIROMED for the detection of SARS-Cov-2 from anterior nasal	REF: B60500 LOT: 20210401B	Nasal swab	lay	Drug store			
		swab	BrArM GZ: 5640-S-096/21						
26	Anhui Deepblue Medical Technology Co.,	COVID-19 (SARS-CoV-2) Antigentestkit (kolloidales Gold)	REF: SL030101N-5 LOT: ST210405	Nasal swab	lay	Online trade			
	Ltd	Ŭ (,	BfArM GZ: 5640-S-086/21						
27	OFM GmbH	Deni COVID-19 Antigen Test –	REF: OFM-LSYBT-NS-1	Nasal swab	lay	Drug store			
		Selbsttest für ZuHause	LOT: P202103003			J			
			BfArM GZ: 5640-S-140/21						
28	Medice Arzneimittel	Medicovid-AG SARS-CoV-2	REF: 1N40C5-4	Nasal swab	lay	Online trade			
	Pütter GmbH & Co. KG	Antigen Selbsttest 5 NASE	LOT: 21041002						
			BfArM GZ: 5640-S-128/21						
29	Shenzhen Watmind Medical Co., Ltd	SARS-CoV-2 Antigen Schnelltest zur Eigenanwendung (kolloidales	REF: LFA0401-5N LOT: 21040904/ 21040704	Saliva (swab)	lay	Supermarket			
		Gold)	BfArM GZ: 5640-032/21						
30	MR Sanicom GmbH	COVID-19 Antigen Schnelltest zur Eigenanwendung (Speichel-/ Spucktest)	Barcode no: 4260729310002 LOT: CAG2104021G BfArM GZ: 5640-S-147/21	Saliva (spit)	lay	Drug store			

32	fameditec	CORA Check-19 Comfort	BfArM GZ: 5640-S-058/21 REF: K590516D/ LOT: 2021022019	Saliva (collected with sponge)	lay	Online trade
			BfArM GZ: 5640-S-154/21			

Table 2: Lepu medical AgPOCT products investigated in this study. AgPOCT products made by Beijing Lepu Medical Technology Co., Ltd. are referred to as Lepu medical AgPOCTs. Lepu medical AgPOCTs were purchased on different online trade platforms. For each Lepu medical AgPOCT, product name, packaging size and intended use (professional (pro) versus layman (lay) use), reference/ barcode number, LOT number as well as BfArM GZ number if applicable are indicated. Production and use-by date are noted in the last column.

Product name	Packaging size (use)	Specifications	Production and use-by date
SARS-CoV-2 Antigen Rapid Test Kit (Colloidal	Pack of 25 tests/	Barcode: 6921807601020 LOT: 21CG2713X	Production date: 06/03/2021 Use-by date: 06/03/2022
Gold Immunochromatography) CE	(pro)	Barcode: same as above LOT: 21CG2715X	Production date: 03/11/2021 Use-by date: 03/11/2022
NASOCHECKcomfort SARS-CoV-2 Antigen Schnelltest Immunchromatographischer Test (kolloidales Gold). Schnell & angenehm! Einfache Anwendung im vorderen Nasenbereich.	Pack of 25 testes (lay)	REF: CG2725(N) Barcode: 4260716970042 LOT: 21CG2722X BfArM GZ: 5640-S-104/21	Production date: 31/03/202 Use-by date: 31/03/2022
NASOCHECKcomfort SARS-CoV-2 Antigen- Schnelltest. Zur Eigenanwendung. Schnell & angenehm! Einfache Anwendung im vorderen Nasenbereich.	Single pack (narrow) (lay)	REF: CG2701N Barcode: 4260716970059 LOT: 21CG2727X BfArM GZ: 5640-S-104/21	Production date: 11/04/2021 Use-by date: 11/04/2022
NASOCHECKcomfort SARS-CoV-2 Antigen- Schnelltest. Zur Eigenanwendung. Schnell & angenehm! Einfache Anwendung im vorderen	Single pack (thick)	REF: CG2701N Barcode: 4260716970059 LOT: 21CG2720X BfArM GZ: 5640-S-104/21	Production date: 26/03/2021 Use-by date: 26/03/2022
Nasenbereich.	(lay)	REF, barcode, BfArM GZ: same as above LOT: 21CG2724X	Production date: 04/04/2021 Use-by date: 04/04/2022

177 **Results**

178 Generation of test samples for standardized AgPOCT evaluation

179 In the present study, we sought to establish a standardized procedure to rapidly 180 assess the sensitivities of a large number of SARS-COV-2 AgPOCTs. To this end, 181 we generated a collection of test samples from pooled nasopharyngeal swabs from 182 SARS-CoV-2 positive tested and negative tested individuals. Ct values of the SARS-CoV-2 positive pools were determined by RT-qPCR and test samples were prepared 183 184 accordingly. The test sample collection comprised four SARS-CoV-2 positive pools 185 with defined viral loads (Ct16, Ct21, Ct25, Ct28) and one SARS-CoV-2 negative pool. 186 Per test sample, >200 aliquots with 120 µł sample volume each were prepared, 187 allowing a quick and standardized evaluation of the analytical sensitivities of a large 188 number of different AgPOCTs.

We estimated that our test sample collection covers a range from $\sim 7.0^{*}10^{8}$ (Ct=16) to 189 ~1.7*10⁵ (Ct=28) SARS-CoV-2 genome copies per ml (Supplemental Table S6). We 190 191 gualitatively validated our test sample collection using the LumiraDx SARS-CoV-2 Ag 192 Test device, which was shown to have a high analytical sensitivity (Krüger et al., 2021). We used 50 µl of a test sample, each for the LumiraDx analysis and for all 193 AgPOCTs evaluated in this study, as described before (Corman et al., 2021; 194 195 Puyskens et al., 2021). All four SARS-CoV-2 positive test samples tested positive for 196 SARS-CoV-2, while the negative test sample was recognized as negative in the 197 LumiraDx analysis.

198 Quantitative and qualitative assessment of AgPOCT analytical sensitivity

199 We tested a total of 32 AgPOCTs (Table 1). 12 AgPOCTs were purchased from local 200 resellers (pharmacies, drugstores, supermarkets). Another 20 tests were purchased 201 online. We performed the tests over 10 days, with the help of four students, during 202 the course of four weeks. Freshly thawed aliquots of the Ct21, Ct25, and Ct28 test samples as well as the negative sample were used. We conducted two to four 203 204 replicates per product, and acquired images of each of the tests at the time points 205 specified by the manufacturers. The Ct16 test sample was only used for AgPOCTs 206 that had low performance with the Ct21 test sample. For quantitative evaluation, 207 signal intensities of the test (T) and the control (C) bands were measured and the 208 ratio of these values (T/C ratio) was determined (Figure 1A). In addition, we scored a 209 binary (positive or negative) test result using visual inspection of the images by four 210 different persons (Figure 1B).

For 31 of 32 investigated AgPOCTs, an average T/C_{Ct25}>0 was determined for all 211 212 virus-containing samples and not for the negative control sample (Figure 1A). This 213 indicates that the digital quantification detects test band signals for 31 AgPOCTs 214 using the Ct25 test sample, albeit sometimes with extremely weak signal intensities. 215 Only for Jointstar, one replicate of the negative test sample resulted in a false 216 positive test band indicated by a $T/C_{Neq.}$ >0. In contrast to the more sensitive digital 217 quantification, visual inspection did only score a positive result for 28 of 31 AqPOCTs 218 with a T/C_{Ct25}>0 (Figure 1B). This also holds true for the visual assessment of the 219 results of technical replicates, e.g. for Jointstar, the negative sample with a T/C_{Neg}>0 220 scored negative in the visual inspection. We could not establish a specific T/C value 221 threshold to explain the results of the visual assessment, indicating that these ratios 222 are product-specific. This can be explained by different dyes and dye-systems, and

by the fact that the visual assessment was conducted using color vision, while for T/C quantification grayscale images were used. We also observed a large coefficient of variation (CV) for some of the tests, in particular for samples with very small T/C ratios, emphasizing weak signals close to the detection limit of the digital quantification (Supplemental Figure S1C).

We grouped the tested AgPOCTs into categories with low (Group III), medium (Group II) and high (Group I) sensitivity based on the reliability to detect a given SARS-CoV-2 positive sample. A sample was considered reliably detected by a given AgPOCT when all or the majority of replicates (at least two out of three or three out of four replicates) of a given sample were scored positive. If none or the minority of replicates of a given sample was detected by the corresponding AgPOCT, reliability requirements were not met.

235 One exception was Lepu medical (Table 1, AgPOCT #20; Table 2, last row) which did not fulfill the requirements for any of these groups. For Group III AgPOCTs with 236 237 the lowest sensitivity, the minimum criterion was that the tests were able to reliably 238 detect the Ct21 sample, and the Lepu medical tests failed this, as they did not even reliably score positive with the Ct16 sample ($\sim 7.0^{*}10^{8}$ copies/ ml; Figure 1B). To 239 240 this product further used individual unprocessed investigate we nasal/ nasopharyngeal swab samples with low Ct values (Ct13.3 to Ct18.4) on this and 241 242 another poor performing product. Comparison of these results to the Ct16 test 243 sample confirmed the low sensitivity of the Lepu medical (Supplemental Figure S2). Only for samples with very low Ct values (Ct~13) T/C ratios were obtained that can 244

be detected easily visually (Supplemental Figure S2A). This suggests that this
product is not completely non-functional, but largely insensitive. Since Lepu medical
AgPOCTs have been widely used in Germany and other European countries we

248 retrieved several Lepu medical products available on different online trade platforms 249 (Table 2). These included two different batches of a Lepu medical product intended for professional use (Table 2, first row, no BfArM GZ number, CE mark). Additionally, 250 251 we included different batches and deviations of the Lepu medical AgPOCT described 252 before (Table 1, AgPOCT #20; Table 2, last three rows). These products were provided with the same BfArM GZ number (5640-S-104/21), which cannot be found 253 254 on the BfArM list anymore (Supplemental Figure S5). We investigated their 255 performance in direct comparison in multiple replicates using Ct16, Ct21 and Ct25 test samples (Supplemental Figure S3). This revealed high variation of the 256 257 determined T/C ratios, with coefficients of variation (CV) ranging from 0.26 to 1.54 and a median CV of 0.50 (Supplemental Figure S4C). In contrast, the median CV of 258 the other 31 investigated AgPOCTs with Ct16-25 test samples was 0.11 259 260 (Supplemental Figure S1C). This indicates a larger variability of the test results not only for different implementations of the Lepu medical AgPOCTs, but also for 261 262 different batches of the same Lepu medical product, compared to all other AgPOCTs 263 investigated in this study.

264 AqPOCTs in Group III only reliably detected the Ct21 sample (~2.2*10⁷ copies/ ml) and include Hygisun, Joinstar and Ritter. Of note is that all of them are saliva based 265 spit tests (Table 1), which are provided with a considerably larger amount of lysis 266 267 buffer (500-1000 µl lysis buffer; Figure 1C) than most other AgPOCTs resulting in an 268 increased dilution of the test sample compared to AgPOCTs for nasal samples, which are provided on average with 320 µl lysis buffer (Figure 1C). The resulting 269 270 higher dilution of the sample together with the possibility of lower virus concentration 271 in saliva versus nasal or nasopharyngeal swabs may further influence the sensitivity 272 of these saliva tests.

273 The large majority of the investigated AgPOCTs (23 out of 32) delivered visible positive results with the Ct25 sample (~1.4*10⁶ copies/ ml, Group II). Among these 274 23 AgPOCTs, positive scoring was fully reproducible in all replicates for 17 275 276 AgPOCTs. AgPOCTs intended for professional use (sorted ascending according to T/C_{Ct25}: Safecare, Realy, Healgen, ACON, Beier, Testsea, BTNX and Biomerica) 277 278 largely cluster in the upper half of the T/C_{Ct25} ranking, while tests licensed for self-279 testing largely cluster in the lower half (sorted ascending according to T/C_{Ct25}: 280 Sanicom, fameditec, OFM, Deepblue, NanoRepro, nal von minden, Teda, Laihe and Boson). Interestingly, among both tests for professional and for layman use, saliva 281 282 spit tests (Realy, Sanicom, fameditec) appear largely inferior compared to nasal 283 swab tests in this setting with the exception of BTNX, which is the sixth highest 284 ranked AgPOCT among all investigated tests. Six AgPOCTs in Group II (sorted 285 ascending according to T/C_{Ct25}: Joysbio, RapiGEN, Hotgen, SD Biosensor, Abbott 286 and Wondfo) failed in one out of three to four replicates to detect the Ct25 sample, 287 which is represented by larger CV values ranging from 0.26 to 0.87 (Supplemental 288 Figure S1C).

Using the Ct28 test sample ($\sim 1.7*10^5$ copies/ ml), 14 out of 32 AgPOCTs yielded a T/C_{Ct28}>0, however, only five reliably scored positive in the visual investigation (Group I). These include (sorted in ascending order according to T/C_{Ct25}) möLab, Medice, MP, Clongene and Watmind, three of which are temporarily licensed for selftesting (Table 1, Supplemental Figure S5). All, except möLab delivered a positive visual result in all three replicates.

Taken together, the data presented here demonstrate that the different SARS-CoV-2 AgPOCTs available deviate largely in the analytical sensitivity of the lateral flow test stripes and provided buffer systems, corresponding more than two orders of magnitude of viral genome copies per ml $(7.0*10^8 \text{ to } 1.7*10^5)$. Additionally, we

299 revealed a great variability in results delivered with different Lepu medical AgPOCT

300 versions and batches emphasizing the need for regular quality monitoring.

301 Discussion

We developed a straight-forward strategy to evaluate the technical sensitivity of AgPOCTs for SARS-CoV-2. Using a set of four SARS-CoV-2 positive reference samples spanning the relevant dynamic range of the typical sensitivity of AgPOCTs $(\sim 1.7*10^5$ to $\sim 2.2*10^7$ SARS-CoV-2 genome copies per ml) we were able to group 32

306 commercially available products into AgPOCT groups with high, average and low 307 sensitivity (Group I-III). Most importantly, we identified one product that did not detect 308 any of the test samples and therefore is considered not suitable for SARS-CoV-2 309 diagnostics.

310 The majority of tests investigated in this study reliably detected the Ct25 test sample 311 as SARS-CoV-2 positive (Group II). Some of these AgPOCTs have been thoroughly 312 characterized, including Abbott, RapiGEN, Healgen, nal von minden and SD 313 Biosensor by Corman and colleagues (Corman et al., 2021) among others (Strömer et al., 2021; Stokes et al., 2021; Merino et al., 2021; Schildgen et al., 2021; 314 315 Seynaeve et al., 2021; Nordgren et al.; Puyskens et al., 2021; Scheiblauer et al., 316 2021; Kohmer et al., 2021; Wagenhäuser et al., 2021; Berger et al., 2021; 317 Jegerlehner et al., 2021; Iglòi et al., 2021; Bekliz et al., 2021; Cubas-Atienzar et al., 318 2021, Haage et al., 2021 and more). Corman and colleagues determined 95% limits 319 of detection for each AqPOCT using 138 SARS-CoV-2 positive clinical samples with viral loads ranging from 1.9*10⁴ to 2.8*10⁹ genome copies per ml. Among the 320 AqPOCTs also tested in this study. Healgen was found to be most sensitive closely 321 322 followed by Abbott, SD Biosensor and nal von minden - all with a 95% limit of 323 detection between 2.3 - 9.3*10⁶ SARS-COV-2 genomes per swab. In contrast, for

324 RapiGEN a 95% limit of detection more than three orders of magnitudes lower was 325 found. This discrepancy in performance between RapiGEN and the above mentioned products is supported by other studies (Brümmer et al., 2021). In our analysis, this 326 327 trend is also reflected even though we cannot resolve the limits of detection in such great detail: For Healgen and nal von minden, detection of the Ct25 test sample 328 (~1.4*10⁶ copies/ ml) was robust with all replicates being positively scored. For 329 330 RapiGEN, Ct25 test sample detection was less reliable and based on the T/C_{Ct25}, this 331 product is ranked in the lowest guarter among all AgPOCTs investigated.

332 Among the 32 investigated AgPOCTs, we identified four reliably well performing AgPOCTs, which detected the Ct28 test sample (~1.7*10⁵ copies/ ml) as SARS-333 CoV-2 positive in all replicates (Group I). These include in ascending order (based on 334 335 T/C_{Ct25}) Medice, MP, Clongene and Watmind. The latter represents the test winner in 336 our study and is also among the best three AgPOCTs out of 122 tested products with 337 a sensitivity of 82 % in samples with Ct values ranging from 17 to 35 corresponding to viral loads of >10⁸ to 10³ SARS-CoV-2 genome copies per ml (Scheiblauer et al., 338 2021). 339

340 Group III includes AgPOCTs with low performance as these only detected the Ct21 341 test sample as SARS-CoV-2 positive. For Joinstar, using Latex beads for visualisation, evidence provided by Scheiblauer and colleagues (2021) suggests that 342 this test is non-functional with 0% sensitivity for all sample panels supporting the low 343 344 ranking of Joinstar in this study. In our analysis we detected very weak bands for the 345 Ct21 and Ct16 test samples, however, these were considerably weaker than for all 346 other tests suggesting the possibility that latex beads used for visualisation do fail to 347 produce a strong signal. Besides Joinstar, Ritter and Hygisun, both saliva spit tests similar to Joinstar, also showed low sensitivity in our studies. While we could not find 348

independent evaluation studies for these products, both can be found on the BfArM
list (as of July 23, 2021; Supplemental Figure S5).

351 Among the low ranked AgPOCTs, the sensitivity of Lepu medical AgPOCT was exceptionally low as this test failed to deliver a visible positive test result in most 352 353 replicates, even for the Ct16 sample. In addition to its poor performance in SARS-354 CoV-2 diagnostics, out of 20 performed Lepu medical tests three tests technically 355 failed, indicated by the absence of the control band. Importantly, this last test is a 356 very popular product in the area where this study was conducted, available at many 357 drugstores and supermarket chains. Of note is also that Lepu medical differs from other AgPOCTs in its design and sample application. Technical failure did not occur 358 359 in any of the other AgPOCTs, in which the immunochromatography paper is 360 embedded in the common plastic cassettes. In other studies tested Lepu medical 361 AqPOCT products performed better (Scheiblauer et al., 2021; Baro et al., 2021), e.g. 362 in the setting of Scheiblauer et al. (2021), a sensitivity of 100 % was found for a Lepu 363 medical AgPOCT and test panel members with Ct values ranging from Ct17 to Ct25. As the AgPOCTs used in these studies are not specified with reference/product and 364 365 LOT number, it is possible that a different Lepu medical product or batch was used. 366 We purchased different Lepu medical AgPOCT products available online and 367 compared performances on the pooled test samples as well as on raw, unprocessed 368 swab samples (Supplemental Figure 3). We tested two batches of a CE-marked 369 product and four Lepu medical with the same BfArM GZ number, but different packaging sizes (Table 2). Indeed, we identified two Lepu medical products 370 371 performing better than shown in Figure 1, however, these performances were not 372 reproducible with other batches of the same product (Supplemental Figure 3) 373 indicating batch-specific variation of the quality. This again emphasizes the 374 importance of a simple method to assay the performance of a product and

375 corresponding batches. Taken together, comparison with published data for some of
 376 the investigated products confirmed our results. Therefore, we provide evidence that
 377 our chosen strategy constitutes a viable solution to rapidly assess the sensitivity of
 378 SARS-CoV-2 AgPOCTs.

379 It is important to mention that the sensitivity of an AqPOCT is the product of multiple 380 factors; the sensitivity of the test stripe and buffer system used are important 381 contributing factors, but not the only ones. Another is the volume of the lysis buffer provided with each AgPOCT. The volume varies between tests of different 382 383 manufacturers resulting in a 2.6- to 20-fold dilution of the test samples during the 384 procedure (Figure 1C). In this study, test results were not corrected for these different 385 dilution factors, because the sample dilution is an internal property of each AgPOCT. 386 By using the same sample volume for each AgPOCT we also neglect potential 387 differences in swab properties, such as absorption volume or sample specimen 388 (saliva, nasal or nasopharyngeal samples), which affect the diagnostic sensitivity of 389 AgPOCTs. However, we note that for tests based on nasal swabs the used volume of 390 50 µl approximates the quantity absorbed by these swabs (Corman et al., 2021). 391 Furthermore, the AgPOCT-specific instructions for self-sampling, which will influence 392 how careful a sample is collected, can also influence the diagnostic sensitivity of a 393 test. In light of these considerations we want to emphasize that this evaluation 394 method only and exclusively focuses on comparing the technical sensitivity of the 395 lateral flow test strips from different test manufacturers, in combination with the provided lysis buffers. 396

397 Currently, there are more than 500 different products available for SARS-CoV-2 398 diagnostics, many of which lack independent assessment of their performance. In 399 most cases the clinical sensitivity values provided by the manufacturer (e.g. in Figure

400 1C) are far >90% (Figure 1C). However, detailed information on specimen collection 401 and viral loads are usually not provided rendering these values largely inconclusive 402 and misleading for laymen. Considering that individual products use different 403 antibodies in varying amounts with different specificities and affinities sometimes 404 recognizing different proteins in the viral particle with differing abundances, and 405 diverse staining methods, these conspicuously similar values for clinical sensitivity 406 given by the manufacturer are also unlikely. Therefore, an independent, rapid and 407 critical evaluation of AqPOCTs available is required in order to determine the realistic performance of AgPOCT relevant to the daily user and especially to identify poor 408 409 performing products. Given the huge number of products available for rapid SARS-410 CoV-2 diagnostics, in-depth studies evaluating the quality of AgPOCTs in a time-411 intensive procedure will not be available any time soon for all products available. 412 Therefore, the procedure presented here involving a reduced test sample collection 413 and minimal labor represents a feasible strategy for prompt evaluation of available 414 AgPOCTs for their usability in SARS-CoV-2 diagnostics. We provide a useful 415 estimation of the limits of detection for the investigated AgPOCTs as the dimensions 416 and trends are comparable to results from much more laborious in-depth studies. 417 Importantly, using this approach we revealed very heterogeneous results for the 418 Lepu medical AgPOCT, which precludes in our opinion the use of this product (or 419 product family) for SARS-CoV-2 diagnostics. In conclusion, we suggest this 420 procedure as a rapid alternative to investigate Covid-19 AgPOCs in the absence of 421 reliable data that validate the performance of a specific product and related batches.

	A Means of T/C ratios				B Pos. scores/ replicates				C Additional information					
	Ct16	cv2^	ct2 ^{E2}	c ²²⁸	4e9.	Ct1%	cr2^	c ¹²⁵	ch28	4e9.	Sample type	Stated sensitivity [%]	Lysis buffer [µl]	Dil. factor
Watmind	n.d.	1,81	0,51	0,08	0,00	n.d.	3/3	4/4	3/3	0/2	sal	90,45	300	6
Clongene	n.d.	1,38	0,48	0,10	0,00	n.d.	3/3	4/4	4/4	0/3	nas	91,4	300	6
MP	n.d.	1,08	0,28	0,04	0,00	n.d.	3/3	3/3	3/3	0/2	nas	96,19	250	5
Boson	n.d.	1,05	0,22	0,02	0,00	n.d.	3/3	5/5	1/2	0/2	nas	96,19	200	4
Biomerica	n.d.	0,78	0,22	0,06	0,00	n.d.	3/3	3/3	1/3	0/3	np	94,7	300	6
BTNX	n.d.	1,04	0,21	0,01	0,00	n.d.	3/3	3/3	0/3	0/3	sal	90,6	300	6
Medice	n.d.	0,92	0,20	0,03	0,00	n.d.	2/2	2/2	2/2	0/2	nas	96,19	250	5
Testsea	n.d.	0,79	0,16	0,01	0,00	n.d.	3/3	3/3	0/3	0/3	nas	97,6	300	6
Beier	n.d.	1,75	0,15	0,00	0,00	n.d.	2/2	2/2	0/2	0/2	np	96,5	450	9
Laihe	n.d.	1,03	0,15	0,01	0,00	n.d.	3/3	4/4	1/3	0/2	nas	95	300	6
ACON	n.d.	0,94	0,15	0,02	0,00	n.d.	3/3	3/3	1/3	0/3	nas	97,1	350	7
Healgen	n.d.	0,93	0,13	0,01	0,00	n.d.	4/4	4/4	1/3	0/4	np	96,72	300	6
möLab	n.d.	0,76	0,12	0,02	0,00	n.d.	2/2	3/3	2/3	0/2	nas/np	97,25	300	6
Teda	n.d.	0,87	0,12	0,00	0,00	n.d.	4/4	4/4	0/3	0/4	nas	93,87	350	7
Wondfo	n.d.	0,98	0,11	0,00	0,00	n.d.	2 /2	2/3	0/2	0/2	nas	97,83	400	8
Abbott	n.d.	1,20	0,09	0,00	0,00	n.d.	4/4	3/4	0/3	0/4	nas	98,1	300	6
nal von minden	0,48	0,50	0,09	0,01	0,00	2/2	4/4	4/4	0/3	0/4	nas	94,1	350	7
Realy	n.d.	0,89	0,09	0,01	0,00	n.d.	2/2	3/3	0/3	0/2	sal	92,9	130	2,6
NanoRepro	0,77	0,56	0,08	0,00	0,00	2/2	3/3	3/3	0/3	0/2	nas	97,33	500	10
SD Biosensor	n.d.	1,12	0,07	0,00	0,00	n.d.	4/4	3/4	0/3	0/4	nas	83,3	300	6
Deepblue	n.d.	0,67	0,07	0,00	0,00	n.d.	2/2	3/3	0/3	0/2	nas	96,4	300	6
OFM	n.d.	0,92	0,07	0,00	0,00	n.d.	3/3	3/3	0/3	0/2	nas	96,8	400	8
Hotgen	n.d.	0,68	0,06	0,00	0,00	n.d.	3/3	3/4	0/3	0/3	nas	95,37	300	6
fameditec	n.d.	0,51	0,06	0,00	0,00	n.d.	3/3	3/3	0/2	0/2	sal	96,3	250	5
Sanicom	1,10	0,63	0,06	0,00	0,00	2/2	3/3	3/3	0/3	0/2	sal	96,1	1000	20
RapiGEN	n.d.	0,99	0,05	0,00	0,00	n.d.	3/3	2/3	0/3	0/3	np	90,2	350	7
Safecare	0,52	0,43	0,05	0,00	0,00	3/3	3/3	3/3	0/3	0/3	np	97,04	350	7
Joysbio	0,30	0,31	0,03	0,00	0,00	2/2	3/3	2/3	0/3	0/3	np	98,13	350	7
Ritter	n.d.	0,16	0,02	0,00	0,00	n.d.	2/2	0/3	0/3	0/2	sal	95,1	500	10
Joinstar	0,10	0,09	0,02	0,00	0,01	2/2	3/3	1/3	0/3	0/3	div	92,2	1000	20
Hygisun	n.d.	0,36	0,01	0,00	0,00	n.d.	3/3	1/3	0/3	0/3	sal	98,94	1000	20
Lepu medical	0,07	0,00	0,00	n.d.	0,00	3/7	1/8	0/1	n.d.	0/2	nas	95,06	150	3

Figure 1: Quantitative and qualitative evaluation of 32 SARS-CoV-2 AgPOCTs in a rapid sensitivity assessment approach. (A) Investigated AgPOCT are listed with the means of T/C ratios (test band (T) intensity to control (C) band intensity) for each Ct test sample. T/C ratios are color-coded in shades of red (highest values with most intense red). Blue color highlights zeros indicating the absence of measurable signal at the test band position. Ct16 test sample was only used on AgPOCTs with exceptionally low performance in medRxiv preprint doi: https://doi.org/10.1101/2021.07.29.21261314; this version posted September 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

detection of the Ct21 sample. AgPOCTs are ranked according to their T/C_{Ct25} ratio. (B) Scoring results of visual inspection for all replicates. Full reproducibility of positive scores in all replicates is highlighted in green, positive scores in the majority of replicates in yellow, positive scores in the minority of replicates in orange and no positive scores in any replicate in light red. n.d. = not determined (grey). Double line indicates the limit of reliable detection of SARS-CoV-2 positive samples (reliability defined by reproducibility of positive scores in all (green) or most (yellow) replicates of a given Ct test sample). (C) Additional information on investigated AgPOCTs: Sample type (nasal (nas)/ nasopharyngeal (np) swab, saliva (sal) or diverse (div)), sensitivities of AgPOCTs according to the corresponding manufacturer's package insert, volumes of provided lysis buffer and the resulting dilution factor for the Ct test samples (V = 50 μ l) are given.





Figure 2: Representative images of SARS-CoV-2 AgPOCTs lateral flow test stripes treated with corresponding Ct test samples. Contrast settings were optimized for each AgPOCT example image set in order to ensure best visibility of the test bands. AgPOCT example images are arranged (from top left to bottom right) according to the ranking presented in Figure 1. Red line indicates the limit of reliable detection (see Figure 1A, B). Arrowheads highlight positions of control (C) and test (T) band.

References 422

423 Baro B., Rodo P., Ouchi D., Bordoy A. E., Saya Amaro E. N., Salsench S. V., Molinos S., Alemany A., Urbals M., Corbacho-Monné M., Millat-Martinez P., Marks 424 M., Clotet B., Prat N., Ara J., Vall-Mayans M., G-Beiras C., Bassat Q., Blanco I., Mitjà 425 O. (2021). Performance characteristics of five antigen-detecting rapid diagnostic test 426 427 (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark 2021.02.11.21251553. Retrieved 428 comparison. MedRxiv, from 429 https://doi.org/10.1101/2021.02.11.21251553

430 Bekliz, M., Adea, K., Essaidi-Laziosi, M., Sacks, J. A., Escadafal, C., Kaiser, L., & 431 Eckerle, I. (2021). Analytical comparison of nine SARS-CoV-2 antigen-detecting rapid diagnostic tests for emerging SARS-CoV-2 variants. MedRxiv, 114(June), 432 433 e00146. Retrieved from https://doi.org/10.1016/j.sciaf.2019.e00146

Berger, A., Nsoga, M. T. N., Perez-Rodriguez, F. J., Aad, Y. A., Sattonnet-Roche, P., 434 435 Gayet-Ageron, A., ... Eckerle, I. (2021). Diagnostic accuracy of two commercial SARSCoV- 2 antigen-detecting rapid tests at the point of care in community-based 436 437 centers. PLoS ONE, 16(3 March 2021), testing 1–12. https://doi.org/10.1371/journal.pone.0248921 438

Brümmer, L. E., Katzenschlager, S., Gaeddert, M., Erdmann, C., Schmitz, S., Bota, 439 M., ... Denkinger, C. M. (2021). The accuracy of novel antigen rapid diagnostics for 440 441 SARS-CoV-2: а livina systematic review and meta-analysis. MedRxiv. 2021.02.26.21252546. Retrieved from https://doi.org/10.1101/2021.02.26.21252546 442

443 Corman, V. M., Haage, V. C., Bleicker, T., Schmidt, M. L., Mühlemann, B., Zuchowski, M., ... Drosten, C. (2021). Comparison of seven commercial SARS-CoV-444 445 2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study. The Lancet Microbe, 5247(21), 1-9. https://doi.org/10.1016/S2666-5247(21)00056-2 446

447 Cubas-Atienzar, A. I., Kontogianni, K., Edwards, T., Buist, K., Thompson, C. R., Williams, C. T., ... Adams, R. (2021). Limit of detection in different matrices of 448 449 nineteen commercially available rapid antigen tests for the detection of SARS-CoV-2 450 Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, 451 L3 5QA UK Liverpool School Tropical. Retrieved from of 452 https://www.medrxiv.org/content/10.1101/2021.03.19.21253950v1.full.pdf

453 Dinnes, J., Deeks, J. J., Adriano, A., Berhane, S., Davenport, C., Dittrich, S., ... Van den Bruel, A. (2020). Rapid, point-of-care antigen and molecular-based tests for 454 455 diagnosis of SARS-CoV-2 infection. Cochrane Database of Systematic Reviews, 2020(8). https://doi.org/10.1002/14651858.CD013705 456

Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel 457 458 und Medizinprodukte (BfArM)). Antigen-Tests zum direkten Erregernachweis des 459 Coronavirus.

460 https://antigentest.bfarm.de/ords/f?p=110:100:16622641307467:...:&tz=2:00

461 Iglòi, Z., Velzing, J., Van Beek, J., Van de Vijver, D., Aron, G., Ensing, R., ... 462 Molenkamp, R. (2021). Clinical evaluation of roche sd biosensor rapid antigen test for

- sars-cov-2 in municipal health service testing site, the netherlands. Emerging 463 Infectious Diseases, 27(5), 1323-1329. https://doi.org/10.3201/eid2705.204688 464

465 Jegerlehner, S., Suter-riniker, F., Jent, P., Bittel, P., & Nagler, M. (2021). Diagnostic 466 accuracy of a SARS-CoV-2 rapid antigen test in real-life clinical settings. International 467 Journal Infectious 118–122. of Diseases, 109, https://doi.org/10.1016/j.ijid.2021.07.010 468

Kohmer, N., Toptan, T., Pallas, C., Karaca, O., Pfeiffer, A., Westhaus, S., ... 469 470 Rabenau, H. F. (2021). The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. Journal of Clinical 471 472 Medicine, 10(2), 328. https://doi.org/10.3390/jcm10020328

- Krüger, L. J., Klein, J. A. F., Tobian, F., Gaeddert, M., Lainati, F., Klemm, S., ... 473 Jones, T. C. (2021). Evaluation of accuracy, exclusivity, limit-of-detection and ease-474 475 of-use of LumiraDxTM Antigen-detecting point-of-care device for SARS-CoV-2. MedRxiv, 1-37. 476
- Merino, P., Guinea, J., Munoz-Gallego, I., González-Donapetry, P., Galán, J. C., 477
- Antona, N., ... Group, the S. P. T. C.-19 validation. (2021). Multicenter evaluation of 478 479 the PanbioTM COVID-19 rapid antigen- detection test for the diagnosis of SARS-
- 480 CoV-2 infection. Clinical Microbiology and Infection, 27(January), 758-761.
- Nordgren, J., Sharma, S., Olsson, H., Jämtberg, M., Falkeborn, T., Svensson, L., & 481 482 Hagbom, M. (2021). SARS-CoV-2 rapid antigen test : High sensitivity to detect 483 infectious virus. Journal of Clinical Virology, 140(January).
- 484 Paul Ehrlich Institute (PEI), Federal Institute for Vaccines and Biomedicines (12 485 2021). Vergleichende Evaluierung der Sensitivität von SARS-CoV-2 July, 486 Antigenschnelltests.
- 487 https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/evaluierung-
- 488 sensitivitaet-sars-cov-2-antigentests-04-12-2020.pdf? blob=publicationFile&v=48

489 Puyskens, A., Krause, E., Michel, J., Nübling, M., Scheiblauer, H., Bourguain, D., ... 490 Nitsche, A. (2021). Establishment of an evaluation panel for the decentralized 491 technical evaluation of the sensitivity of 31 rapid detection tests for SARS-CoV-2 492 diagnostics. MedRxiv.

- Scheiblauer, H., Filomena, A., Nitsche, A., Puyskens, A., Corman, V. M., Drosten, 493 494 C., ... Nübling, C. M. (2021). Comparative sensitivity evaluation for 122 CE-marked 495 SARS-CoV-2 antigen rapid tests. MedRxiv, 2021.05.11.21257016. Retrieved from 496 http://medrxiv.org/content/early/2021/05/12/2021.05.11.21257016.abstract
- 497 Schildgen, V., Demuth, S., Lüsebrink, J., & Schildgen, O. (2021). Limits and 498 opportunities of sars-cov-2 antigen rapid tests: An experienced-based perspective. 499 Pathogens, 10(1), 1–7. https://doi.org/10.3390/pathogens10010038
- Seynaeve, Y., Heylen, J., Fontaine, C., Maclot, F., Meex, C., Diep, A. N., ... Descy, 500 501 J. (2021). Evaluation of Two Rapid Antigenic Tests for the Detection of SARS-CoV-2 502 in Nasopharyngeal Swabs. Journal of Clinical Medicine, (M), 1–9.

Stokes, W., Berenger, B. M., Portnoy, D., Scott, B., Szelewicki, J., Singh, T., ... 503 Tipples, G. (2021). Clinical performance of the Abbott Panbio with nasopharyngeal, 504 throat, and saliva swabs among symptomatic individuals with COVID-19. European 505 506 Journal Clinical Microbiology and Infectious of Diseases, 3-8. 507 https://doi.org/10.1007/s10096-021-04202-9

508Strömer, A., Rose, R., Schäfer, M., Schön, F., Vollersen, A., Lorentz, T., ...509Krumbholz, A. (2021). Performance of a point-of-care test for the rapid detection of510sars-cov-2antigen.Microorganisms,511https://doi.org/10.3390/microorganisms9010058

512 **Wagenhäuser**, I., Knies, K., Rauschenberger, V., Eisenmann, M., McDonogh, M., 513 Petri, N., ... Krone, M. (2021). Clinical performance evaluation of SARS-CoV-2 rapid 514 antigen testing in point of care usage in comparison to RT-qPCR. EBioMedicine, 69, 515 103455. https://doi.org/10.1016/j.ebiom.2021.103455

516 World Health Organization (WHO; 11 September 2020). Antigen-detection in the

517 diagnosis of SARS-CoV-2 infection using rapid immunoassays: Interim guidance.

518 WHO/2019-nCoV/Antigen_Detection/2020.

519 Acknowledgements

- 520 We thank Helena Kettern, Vincent T. Jaschinski and Larissa Karl for their flexible
- 521 help with AgPOCT image acquisition. Furthermore, we thank M. Krogemann for help
- 522 with AgPOCT result scoring. Additionally, we thank M. Meurer for helpful